A5100735903- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Gastrointestinal Tumor Research and Treatment
- Melanoma and MAPK Pathways
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Cancer Mechanisms and Therapy
- Ferroptosis and cancer prognosis
- Metastasis and carcinoma case studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- Smart Agriculture and AI
- Sarcoma Diagnosis and Treatment
- Traditional Chinese Medicine Studies
- Gastrointestinal disorders and treatments
- Fungal Biology and Applications
- Hepatitis B Virus Studies
- Cancer, Hypoxia, and Metabolism
- Cutaneous Melanoma Detection and Management
- Liver Disease Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Abdominal Surgery and Complications
- Pancreatitis Pathology and Treatment
- Botanical Studies and Applications
Sun Yat-sen University
2024
81th Hospital of PLA
2008-2024
Nanjing University
2023-2024
Nanjing General Hospital of Nanjing Military Command
2020-2024
Sun Yat-sen University Cancer Center
2024
Hebei Yiling Hospital
2024
Shanghai University of Medicine and Health Sciences
2023
Jiangsu Cancer Hospital
2020-2023
Nanjing Medical University
2023
Nanjing University of Chinese Medicine
2018-2022
Donafenib, a novel multikinase inhibitor and deuterated sorafenib derivative, has shown efficacy in phase Ia Ib hepatocellular carcinoma (HCC) studies. This study compared the safety of donafenib versus as first-line therapy for advanced HCC.This open-label, randomized, parallel-controlled, multicenter II-III trial enrolled patients with unresectable or metastatic HCC, Child-Pugh score ≤ 7, no prior systemic from 37 sites across China. Patients were randomly assigned (1:1) to receive oral...
Primary liver cancer, of which around 75-85% is hepatocellular carcinoma in China, the fourth most common malignancy and second leading cause tumor-related death, thereby posing a significant threat to life health Chinese people.Since publication Guidelines for Diagnosis Treatment Liver Cancer China June 2017, were updated by National Health Commission December 2019, additional high-quality evidence has emerged from researchers worldwide regarding diagnosis, staging, treatment that requires...
We evaluated the efficacy and safety of pembrolizumab in patients from Asia with previously treated advanced hepatocellular carcinoma (HCC).
Hepatocellular carcinoma (HCC) is a common cancer globally and leading cause of cancer-related deaths. Although early-stage disease may be curable by resection, liver transplantation or ablation, many patients present with unresectable have poor prognosis. Combination treatment atezolizumab (targeting PD-L1) bevacizumab VEGF) in the recent IMbrave150 study was shown to effective an acceptable safety profile HCC. Herein, we discuss this novel combination context immune environment, summarize...
4117 Background: Patients (pts) with advanced CCA who progressed on or after first line chemotherapy have no approved treatment options. Fibroblast growth factor receptor (FGFR) gene alterations are observed in many tumor types including 14-17% CCA. Erdafitinib, an orally bioavailable, selective pan-FGFR kinase inhibitor, has shown clinical activity against solid tumors FGFR alterations. Methods: LUC2001 is open-label, multicenter, Ph2a study pts (FoundationOne), ≥ 1 prior treatment. The...
4506 Background: Sorafenib is still the standard first-line therapy for advanced hepatocellular carcinoma (HCC). Donafenib, a novel multikinase inhibitor, showed potential benefits in previous phase Ib study HCC. Methods: In this open-label, randomized II/III trial (ZGDH3), patients with unresectable or metastatic HCC, Child-Pugh liver function score ≤ 7, and no prior systemic were enrolled from 37 sites across China (1:1) to receive oral donafenib (0.2 g) sorafenib (0.4 twice daily until...
Summary Background Immune checkpoint inhibitor (ICI) combination therapy offers a new option for treatment of unresectable intrahepatic cholangiocarcinoma (uICC). Aim To compare the effect different anti‐PD‐1 therapies as first‐line treatments uICC. Methods This study included 318 patients who received chemotherapy alone (Chemo), plus (ICI‐chemo), targeted (ICI‐target) or and (ICI‐target‐chemo) first line uICC from 22 centres in China. The primary endpoint was progression‐free survival...
Abstract Aim Dasatinib is a small molecule tyrosine kinase inhibitor with multiple targets including kit, PDGFR, and SRC. This prospective study evaluated the efficacy safety of dasatinib as third‐line treatment for gastrointestinal stromal tumors (GIST). Methods The enrolled adult patients (≥18 years age) histologically confirmed unresectable and/or metastatic GIST whose disease progressed despite imatinib sunitinib therapy. (50 mg twice daily) was given orally 1 week escalated to 70 daily...
Next-generation sequencing (NGS) technology is capable of millions or billions DNA molecules simultaneously. Therefore, it represents a promising tool for the analysis molecular targets initial diagnosis disease, monitoring disease progression, and identifying mechanism drug resistance. On behalf Tumor Biomarker Committee Chinese Society Clinical Oncology (CSCO) China Actionable Genome Consortium (CAGC), present expert group hereby proposes advisory guidelines on clinical applications NGS...
Hepatocellular carcinoma (HCC), commonly known as primary liver cancer, is a major cause of malignant tumors and cancer-related deaths in China, accounting for approximately 85% all cancer cases the country. Several guidelines have been used to diagnose treat cancer. However, these provide broad definition classifying advanced with an emphasis on singular approach, without considering treatment options individual patients. Therefore, it necessary establish comprehensive practical expert...
Abstract Background Numerous gene signatures predicting the prognosis of bladder cancer have been identified. However, a tumor-specific T cell signature related to immunotherapy response in remains under investigation. Methods Single-cell RNA and TCR sequencing from Gene expression omnibus (GEO) database were used identify cell-related genes cancer. Subsequently, we constructed (TstcSig) validated its clinical relevance for multiple cohorts. Further analyses explored immune characteristics...
Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, clinical benefit. To date, no guideline or consensus has been published on TKI-associated adverse reactions. Therefore, Chinese Society Surgeons for Gastrointestinal Stromal Tumor Medical Doctor Association organized an expert panel discussion involving representatives from surgery, medical oncology,...
Background: This study investigates the potential predictors of nivolumab plus chemotherapy or multitarget tyrosine kinase inhibitor (TKI) treatment response in patients with recurrent hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Methods: Patients virus-related HCC who underwent TKI between July 2017 and June 2019 at Jinling Hospital China were retrospectively evaluated included this study. These also had both complete medical charts follow-up data available. Overall...